Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality

Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

(2021) · doi:10.1101/2021.03.01.433466 · Cited by 626

Healthcare workers’ willingness to receive COVID-19 booster dose and associated factors in the Democratic Republic of the Congo

Kolomba, B. M., Luhembwe, F. K., Ndala, D. B. B., Ilunga, P. K. W., Paul, C. M., Kitenge, A. N., Lumbule, J. N., Umba, E. K. N., Ilunga, A. U., Miema, J. M., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2357214 · Cited by 2

Evaluating COVID-19 Vaccine Efficacy Using Kaplan–Meier Survival Analysis

Hilal, W., Chislett, M. G., Wu, Y., Snider, B., McBean, E. A., Yawney, J., & Gadsden, S. A. (2024) · BioMedInformatics · doi:10.3390/biomedinformatics4040113 · Cited by 2

Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19

Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Challener, D. W., Breeher, L. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac058 · Cited by 2

The attitude of fully vaccinated individuals towards COVID-19 vaccine booster dose: a transverse study from Jordan

Abuhammad, S., Alzoubi, K. H., Khabour, O. F., Hamaideh, S. H., & El-zubi, M. K. (2022) · Journal of Pharmaceutical Health Services Research · doi:10.1093/jphsr/rmac047 · Cited by 2

The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration

Swadźba, J., Anyszek, T., Panek, A., Chojęta, A., Piotrowska-Mietelska, A., & Martin, E. (2023) · Vaccines · doi:10.3390/vaccines11020278 · Cited by 3

A Novel Approach to Obtain Vaccine Effectiveness Continuous Profiles. Example Case: COVID-19 in Elderly Mexicans

González-Sánchez, Ó. A., González-Ortiz, L. J., Sánchez-Peña, M. J., Pulido, H. G., Cervantes, O., Márquez‐Sandoval, F., Hernández‐Bello, J., Casillas, N., & Muñóz-Valle, J. F. (2023) · Vaccines · doi:10.3390/vaccines11040719 · Cited by 2

Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

Edelman-Klapper, H., Rabinowitz, K. M., Zittan, E., Shitrit, A. B., Goren, I., Avni‐Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11071263 · Cited by 2

Importation Risk Stratification for COVID19 using Quantitative SerologyPreprint

Williams, D. E. (2021) · medRxiv · doi:10.1101/2021.09.29.21264323 · Cited by 2

The impact of vaccinating adolescents and children on COVID-19 disease outcomesPreprint

Ainslie, K. E. C., Backer, J. A., de Boer, P., van Hoek, A. J., Klinkenberg, D., Altes, H. K., Leung, K. Y., de Melker, H. E., Miura, F., & Wallinga, J. (2021) · medRxiv · doi:10.1101/2021.10.21.21265318 · Cited by 2

In Vitro Inhibition of SARS-CoV-2 Infection by Dry Algae PowdersPreprint

García-Ruíz, D., Villalobos-Sánchez, E., Alam-Escamilla, D., & Elizondo‐Quiroga, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1416575/v1 · Cited by 2

An analysis of prevalence, disability-adjusted life years of asthma in China: results from the GBD Study 2019 of the G20Preprint

Liu, M., Gan, H., Lin, Y., Lin, R., Xue, M., Zhang, T., Cheng, Z. J., & Sun, B. (2022) · Research Square · doi:10.21203/rs.3.rs-1988909/v1 · Cited by 2

Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2

Wu, J., Shi, X., Tao, B., Zhan, Y., Lu, X., & Wang, J. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.028 · Cited by 1

The Effect of COVID-19 Epidemic Pandemic and Preventive Measures in India: A Review

Prabha, C., Agarwal, S., & Goel, A. (2022) · International Journal of Management and Humanities · doi:10.35940/ijmh.l1506.0881222 · Cited by 1

Immunity and COV ID-19 vaccines. Revisiting the bases

Ruiz-Romero, J. A., Quijano-Castro, F. O., López-Romero, R., Chavarría-Arriaga, X., Torres, M., & Salcedo, M. (2022) · Gaceta Médica de México · doi:10.24875/gmm.22000092 · Cited by 5

Analyse épidémiologique nationale portant sur l'association entre la vaccination contre la COVID-19 et l'incidence des cas de COVID-19 au Canada, de janvier à août 2021

Agence de la santé publique du Canada, É. D. L. S. D. L. C.-1. (2023) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v49i04a07f · Cited by 1

Social Media Text Analysis on Public’s Sentiments of Covid-19 Booster Vaccines

Kristian, Y., Yesenia, A. V., Safina, S., Pravitasari, A. A., Sari, E. N., & Herawan, T. (2023) · Lecture notes in computer science · doi:10.1007/978-3-031-37105-9_15 · Cited by 1

IODINE AS A POTENTIAL FRONT-LINE DEFENSE AGAINST COVID-19: A LITERATURE REVIEW

Bhowmik, A. D., Bhowmik, N. D., & Baisya, O. (2023) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2023.v16i7.47522 · Cited by 1

ANALYSIS OF TRANSMISSION DYNAMICS OF SARS-COV-2 UNDER SEASONAL CHANGE

Wang, J., JIANG, W., Yang, M., & Shao, W. (2023) · Fractals · doi:10.1142/s0218348x2350113x · Cited by 1

Persepsi Masyarakat Kota Manado Terhadap Vaksin Booster Covid-19 sebagai Syarat Berwisata

Mandak, K. A. G., Pangemanan, D. H. C., & Doda, D. V. D. (2023) · Medical Scope Journal · doi:10.35790/msj.v6i1.45458 · Cited by 1

Mathematical Optimization Strategy for Effectiveness Profile Estimation in Two-Dose Vaccines and Its Use in Designing Improved Vaccination Strategies Focused on Pandemic Containment

González-Sánchez, Ó. A., Zaldívar, D., Cuevas, E., & González-Ortiz, L. J. (2024) · Vaccines · doi:10.3390/vaccines12010081 · Cited by 1

A Retrospective Analysis of Indoor CO2 Measurements Obtained with a Mobile Robot during the COVID-19 Pandemic

Palacín, J., Rubies, E., & Clotet, E. (2024) · Sensors · doi:10.3390/s24103102 · Cited by 1

Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients

Cui, J., Wang, L., Ghavamian, A., Li, X., Wang, G., Wang, T., Huang, M., Ru, Q., & Zhao, X. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03402-9 · Cited by 1

Rapid Review of COVID-19 Mitigation Within a Clinical Trials Unit: The UZ- CTRC Experience

Patience, M. T., Mutambanengwe-Jacob, M. T., Tichaona, V., Nicol, N., Betty, K. S., Mutsa, B.-D., & Mike, C. Z. (2021) · International Journal of HIV/AIDS Prevention Education and Behavioural Science · doi:10.11648/j.ijhpebs.20210702.14

SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria

Mara, E., Mader, T., Gratzer, J., Hochegger, S., & Pekar, T. (2022) · Clinical Immunology Communications · doi:10.1016/j.clicom.2022.08.001 · Cited by 1

Pros and Cons for COVID-19 Vaccination and Boost of Young Adults in Light of Recent Literature

Nemunaitis, J. J., Lehmann, P., & Willey, J. C. (2022) · Medical Research Archives · doi:10.18103/mra.v10i8.2943 · Cited by 1

Optimal control strategy for the administration of the third vaccine dose in the treatment of pandemic COVID-19

Khaloufi, I., Benfatah, Y., Lafif, M., Ghazaoui, A., & Rachik, M. (2023) · Mathematical Modeling and Computing · doi:10.23939/mmc2023.03.841 · Cited by 1

Coronavirus disease 2019 in the occupational settings

Monaco, M. G. L., Spiteri, G., & Porru, S. (2022) · Current Opinion in Epidemiology and Public Health · doi:10.1097/pxh.0000000000000001 · Cited by 1

Using a physical model and aggregate data from Israel to estimate the current (July 2021) efficacy of the Pfizer-BioNTech vaccinePreprint

De-Leon, H., & Pederiva, F. (2021) · medRxiv · doi:10.1101/2021.08.10.21261856 · Cited by 1

Systems immune profiling of variant-specific vaccination against SARS-CoV-2Preprint

Peng, L., Park, J. J.-Y., Fang, Z., Zhou, X., Dong, M. B., Xiong, Q., Lin, C., & Chen, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.02.471028 · Cited by 1

Distinguishing COVID-19 infection and vaccination history by T cell reactivityPreprint

Yu, E. D., Wang, E. W., Garrigan, E., Goodwin, B., Sutherland, A., Chang, J., Gálvez, R. I., Mateus, J., Rawlings, S. A., Smith, D. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.15.472874 · Cited by 1

Individual vaccine efficacy variation with time since mRNA BNT162b2 vaccination estimated by rapid, quantitative antibody measurements from a finger-prick samplePreprint

Vargas, M. J. T., Chandrasekhar, M., Kwon, Y. J., Deijs, G. S., Corazza, C. M. O. W., Chai, A., Binedell, R. L., Jose, E., Govind, B., Huyet, L., et al. (2021) · medRxiv · doi:10.1101/2021.11.30.21267102 · Cited by 1

Model analysis of vaccination effectiveness by state in the United StatesPreprint

Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3987537 · Cited by 1

Genomic monitoring unveils a high prevalence of SARS-CoV-2 Omicron variant in vaccine breakthrough casesPreprint

Campos, G. S., Giovanetti, M., de Moraes, L. E. P., da Hora, H. S., Alcantara, K. V. O. M. D., & Sardi, S. I. (2022) · medRxiv · doi:10.1101/2022.02.16.22271059 · Cited by 1

Risk of SARS-CoV-2 Reinfections in Children: Prospective National Surveillance, January 2020 to July 2021, EnglandPreprint

Mensah, A. A., Campbell, H., Stowe, J., Seghezzo, G., Simmons, R., Lacy, J., Bukasa, A., O'Boyle, S., Ramsay, M. E., Brown, K. E., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3979660 · Cited by 1

Appendix for Vaccinating Against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness EvidencePreprint

Black, B. S., & Thaw, D. B. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4659854 · Cited by 1

Humoral immune responses against seasonal coronaviruses predict efficiency of SARS-CoV-2 spike targeting, FcγR activation, and corresponding COVID-19 disease severityPreprint

Garrido, J. L., Medina, M. A., Bravo, F., McGee, S., Fuentes, F., Calvo, M., Bowman, J., Bahl, C., Barria, M. I., Brachman, R. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.14.460338

SARS-CoV-2 epidemic in the South American Southern cone: can combined immunity from vaccination and infection prevent the spread of Gamma and Lambda variants while easing restrictions?Preprint

Fiori, M., Bello, G., Wschebor, N., Lecumberry, F., Ferragut, A., & Mordecki, E. (2021) · medRxiv · doi:10.1101/2021.09.16.21263701v1

COVID 19 breakthrough infection risk: a simple physical model describing the dependence on antibody concentrationPreprint

Williams, D. E. (2021) · Research Square · doi:10.21203/rs.3.rs-1051588/v1

Effectiveness of Vaccination against Reported SARS-CoV-2 Infection in United States Coast Guard Personnel between May and August 2021: A Time-Series AnalysisPreprint

Iskander, J. K., Frost, J., Russell, S., Ahluwalia, J. S., Ward, E., Steiner, S., Thomas, D. L., & Michaud, P. R. (2021) · medRxiv · doi:10.1101/2021.11.19.21266537

Grippe et Covid-19

Jaffal, K., & Mascitti, H. (2021) · Infectious Diseases Now · doi:10.1016/s2666-9919(21)00555-8

Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients who Were Vaccinated with Coronavac or Unvaccinated: An Analytical, Cross Sectional StudyPreprint

Yavuz, S. Ş., Tunçer, G., Aydın, Ö. A., Aydın, M., Pehlıvanoglu, F., Tok, Y., Meşe, S., Gündüz, A., Geyiktepe-Güçlü, C., Özdoğan, İ., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1063869/v1

Should Bangladeshi Need A Covid Vaccine Booster Dose?

Ahmed, M. (2021) · Bangladesh Journal of Medical Microbiology · doi:10.3329/bjmm.v15i1.57804

Dynamics in COVID-19 Symptoms During Different Waves of the Pandemic Among Children Infected with SARS-CoV-2Preprint

Ben‐Tov, A., Lotan, R., Gazit, S., Chodick, G., Perez, G., Mizrahi-Reuveni, M., & Patalon, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1289584/v1

Mosaic receptor-binding domain nanoparticles induce protective immunity against SARS-CoV-2 challengesPreprint

Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Chang, Y. Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.18.480994

“Booster Vaccine” to Mitigate the Threat of “Emerging COVID-19 Variants”

Pandian, M., Veepanattu, P., Moni, M., & Sathyapalan, D. T. (2021) · Amrita Journal of Medicine · doi:10.4103/amjm.amjm_5_22

Short-term SARS-CoV-2 Re-infection Rate in Vaccinated Health Workers based on Received Vaccines: A Cross-sectional Study

Sinaei, R., Jafari, M., Karamozian, R., Pezeshki, S., Sinaei, R., Robati, F. K., Yeganeh, M. H., & Najafzadeh, M. J. (2023) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x19666230911094423

Evaluation of the Effects of Coronavirus Vaccination Status on Inpatient Demographics and Clinical and Laboratory Data

Girgin, A., Ileri, F., Kaya, S., & Koca, N. (2023) · Cureus · doi:10.7759/cureus.47794

Tendances des conséquences de la COVID-19 selon le statut vaccinal au Canada, décembre 2020 à janvier 2022

Dam, D., Merali, S., Chen, M., Coulby, C., Fane, B. H. M., Bang, F., Robson, J., & David, S. (2024) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v50i12a05f

Additional file 2 of Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China

Tang, S., Wang, X., Tang, B., He, S., Yan, D., Huang, C., Shao, Y., Xiao, Y., & Cheke, R. (2023) · Figshare · doi:10.6084/m9.figshare.23305097

COVID-19 Vaccine Breakthrough Infections and Compliance to Non-Pharmaceutical Public Health Interventions: A Nested Case-Control Study

Mundodan, J. M., Sallam, M., Ravi, R. P., Abuqaoud, A., Abualqasim, M. S. A. S., Elbourdiny, A. A. M., Khogali, H., Al-Shamali, M. H. M. A., Albayat, S. S., & Al‐Romaihi, H. E. (2024) · Journal of Vaccines Immunology and Immunopathology · doi:10.29011/2575-789x.0001111

Eosinophils protect against SARS-CoV-2 following a vaccine breakthrough infectionPreprint

Moore, K. M., Foster, S. L., Kar, M., Floyd, K. A., Elrod, E. J., Williams, M. E., Velden, J. W. V., Ellis, M. L., Malik, A. A., Wali, B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.08.607190

Effectiveness of COVID-19 Vaccines Against Delta Variant: The Case of the Maldives

Raheem, R. A., Huda, A., Shamah, F., Murushidha, M., Mohamed, N., Ahmed, I. N., Rafeeg, F. N., Aroosha, A., Jamal, S., Nazeem, A., et al. (2025) · Asia Pacific Journal of Public Health · doi:10.1177/10105395251325627

Impact of vaccination on the development of acute kidney injury in Japanese COVID-19 patients: a retrospective observational analysis

Taito, K., Oka, M., Sugimoto, H., Fukagawa, H., Izawa, A., Tsuchiya, T., Matsuno, S., Yamanaka, N., Yumura, W., Suzuki, N., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02740-6

Additional file 1 of SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review

Jing, X., Han, M., Wang, X., & Zhou, L. (2023) · Figshare · doi:10.6084/m9.figshare.24089183

Additional file 1 of Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China

唐三一, Wang, X., Tang, B., He, S., Yan, D., Huang, C., Shao, Y., Xiao, Y., & Cheke, R. (2023) · Figshare · doi:10.6084/m9.figshare.23305094

Additional file 2 of The role of Israeli researchers in the scientific literature regarding COVID-19 vaccines

Rosen, B., Davidovitch, N., Chodick, G., & Israeli, A. (2022) · Figshare · doi:10.6084/m9.figshare.21621984

Additional file 2 of Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients

Cui, J., Wang, L., Ghavamian, A., Li, X., Wang, G., Wang, T., Huang, M., Ru, Q., & Zhao, X. (2024) · Figshare · doi:10.6084/m9.figshare.27140602

Additional file 1 of Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients

Cui, J., Wang, L., Ghavamian, A., Li, X., Wang, G., Wang, T., Huang, M., Ru, Q., & Zhao, X. (2024) · Figshare · doi:10.6084/m9.figshare.27140599

Additional file 1 of Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24077073

Additional file 1 of The role of Israeli researchers in the scientific literature regarding COVID-19 vaccines

Rosen, B., Davidovitch, N., Chodick, G., & Israeli, A. (2022) · Figshare · doi:10.6084/m9.figshare.21621981

A dynamic model of COVID-19 infection quantifies the impact of preventive interventions on the infection of severely immunocompromised subjects in the United Kingdom

Pin, C., Taylor, S., Ferreira, C., Arnetorp, S., & Kimko, H. H. C. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341331

Etude phénotypique des variants du SARS-CoV-2 et de leur sensibilité aux anticorps neutralisants et monoclonaux

Boschi, C. (2022) · theses.fr (ABES) · doi:10.70675/2523e81cz0815z4a31za5cczaee28bce546b

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in AdolescentsPreprint

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · medRxiv · doi:10.1101/2022.01.04.22268776 · Cited by 16

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac315 · Cited by 22

P-2061. Long-term Follow Up of Pfizer-BioNTech BNT162b2 mRNA Vaccinations Reveals Persistent Disparities between SARS-CoV-2 Naive and Infected Individuals in the Context of Breakthrough Infections

Marklund, E., Lundgren, A., Bemark, M., Nyström, K., Li, Y., Yilmaz, A., Andersson, L., & Gisslén, M. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae631.2217

Long-Term Comparative Effectiveness of BNT162b2 Vaccine on SARS-CoV-2 Infection in Adolescents. A Register-Based Real-World Study from DenmarkPreprint

Cajar, M. D., Andersen, M. P., Krogager, M. L., Schou, M., Kragholm, K. H., Fosbøl, E. L., Køber, L., & Torp-Pedersen, C. T. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4399760